April 25, 2023 06:17 PM EDTUpdated 06:38 PM

With proxy fight deadline a month away, Illumina announces plans to cut $100M in costs

Jared Whitlock

Features Editor

Illumina will cut $100 million in annual costs amid a proxy fight with activist investor Carl Icahn, the company said in

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

Corvus' early-phase atopic dermatitis data prompt stock rally

AI biotech Insilico Medicine goes for third attempt at Hong Kong IPO

'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis

GSK awaits Nucala decision after FDA target date passes

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges